comprehensive -WSS

comprehensive

author：hotspot 2025-09-29 14:00:15 - browse：14

A sign of Elevance Health behind some flowers — coverage from STAT — Michael Conroy/AP

Paul Marchetti, the head of insurer Elevance Health’s pharmacy benefit manager, has left the company amid a wave of consumer complaints about patients receiving incorrect medicines or being unable to get their prescriptions filled.

Elevance did not confirm Marchetti’s departure as the president of CarelonRx, but according to his Linkedin profile, he left the company in May.

Elevance, the second-largest commercial health insurer in the country by market share, uses its CarelonRx subsidiary to manage its pharmacy business. In online complaints, CarelonRx customers point toward January 1 as the date when issues with obtaining their prescriptions from the company began. The reported problems include safety issues like receiving other people’s medications or receiving medications they discontinued years ago.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： FDA proposes changes to key medical devices approval pathway

focus

WSS

After half a century, Israel moves to evict squatter from his cave home on the beach

IRA could hurt research into orphan drugs for rare diseases

EU fines Illumina $475 million over Grail acquisition

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Food makers tried to stack nutrition panel with preferred experts

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

focus

Wildfire smoke exposes gaps in outdoor worker protections

A common UTI test for kids haunts adults as a traumatic 'nightmare'

BioMarin wins approval for gene therapy to treat hemophilia A

Blinken talks high

Hepatitis C has a cure — but many Americans still lack access to it

After half a century, Israel moves to evict squatter from his cave home on the beach

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

Psychedelics group wrestles with new pharma identity

FDA proposes changes to key medical devices approval pathway

knowledge

Long Covid needs a new name — and a new frame

China sends large group of warplanes, navy ships towards Taiwan in forceful display

Telehealth for opioid use disorder is lifesaving

Grail's uphill battle for Medicare to cover its cancer screening test

A Greenpeace activist is fined for crash

Inflation cooled significantly in June, bringing price hikes close to normal levels

focus

hotspot

leisure time

explore